A Cross-Sectional Study of Acne Vulgaris and Associated Risk Factors Among Adolescents
International Journal of Pharmaceutical Quality Assurance · 30.04.2026 · 17 (04)
DOI: 10.25258/ijpqa.17.4.50 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.04.2026. Verfasst von Deepak Kumar und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Acne vulgaris is a common chronic inflammatory disorder of the pilosebaceous unit that frequently affects adolescents and can significantly impact physical appearance and quality of life. Various genetic, dietary, and lifestyle factors contribute to its development and severity.
Aim
To assess the clinical profile of acne vulgaris and identify associated risk factors among adolescents. Methodology: A hospital-based cross-sectional observational study was conducted among 80 adolescents aged 10–19 years attending the Department of Skin & VD, Anugrah Narayan Magadh Medical College and Hospital, Gaya ji, Bihar. Data were collected using a structured questionnaire and clinical examination. Associations between risk factors and acne severity were analyzed using appropriate statistical tests, with p
Zitieren
APA
Kumar, D., Hussain, M., & Pravakar, P. P. (2026). A Cross-Sectional Study of Acne Vulgaris and Associated Risk Factors Among Adolescents. International Journal of Pharmaceutical Quality Assurance, 17(04). https://doi.org/10.25258/ijpqa.17.4.50
Vancouver
Kumar D, Hussain M, Pravakar PP. A Cross-Sectional Study of Acne Vulgaris and Associated Risk Factors Among Adolescents. International Journal of Pharmaceutical Quality Assurance. 2026;17(04). doi:10.25258/ijpqa.17.4.50
BibTeX
@article{Kumar2026,
author = {Kumar, Deepak and Hussain, Mobarak and Pravakar, Prem Prakash},
title = {A Cross-Sectional Study of Acne Vulgaris and Associated Risk Factors Among Adolescents},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {04},
doi = {10.25258/ijpqa.17.4.50}
}
EUVIMED